 |
European Pre-Filled Syringes
January 18, 2012—January 19, 2012
London, United Kingdom
Latin America: Regulatory Compliance Requirements for Life Science Products
(Focus: Brazil, Mexico, Argentina)
January 19, 2012—January 20, 2012
San Francisco, CA, USA
Enhancing Drug Bioavailability & Solubility
January 25, 2012—January 26, 2012
Boston, MA, USA
Novel Immunotherapeutics Summit
January 30, 2012—January 31, 2012
San Diego, CA, USA
Cool Chain Logistics Europe 2012
January 30, 2012—February 1, 2012
Basil, Switzerland 
|
|
|
 |
 |
|
USP Announces Proposed Standard for Supply-Chain Integrity
The US Pharmacopeia announced a draft standard containing best practices for ensuring that drugs can be traced to their original manufacturer, are not counterfeited or adulterated, and can be transported to their intended destination without compromising quality. 
BMS to Acquire Inhibitex for $2.5 Billion
Bristol-Myers Squibb (BMS) has signed an agreement to acquire the clinical-stage biotechnology company Inhibitex in a deal worth approximately $2.5 billion. The transaction will provide BMS with a potential candidate currently in Phase II development for the treatment of hepatitis C.
Novartis Issues Recall and Suspends Operations at US Facility
Novartis Consumer Health has announced a voluntary recall of all lots of select, bottle-packaged configurations of Excedrin, NoDoz, Bufferin and Gas-X Prevention. The recall follows consumer complaints of chipped or broken pills and inconsistent bottle packaging line clearance practices that could lead to stray tablets, capsules or caplets from other Novartis products. |
 Peristaltic pumps feature user-friendly applications
Wheaton’s UniSpense Pro and OmniSpense Elite are designed to simplify and accelerate laboratory-throughput small filling operations. The devices also can dispense or aspirate multiple aliquots. The pumps are operated by an icon-driven interface that features a large display screen to enhance visibility and clarity. The systems are operated with a backlit 5-in. liquid crystal display with a chemical-resistant keypad, and options are displayed as large icons for quick operation and easy recognition in any language.
The pumps’ angled, polarized display is intended for use under a fume hood or biological safety cabinet. The pumps also contain a single intuitive calibration screen, designed for user-friendliness, that walks the operator through the process stepwise, thus eliminating scroll-through menus and the need for instruction manuals. In addition, the OmniSpense Elite and UniSpense Pro can be outfitted and programmed for specific processes. Once saved, these programs can be recalled easily, thus ensuring a quick application turnaround. |
|
|
 |
|
Bayer HealthCare through its US Innovation Center plans to provide shared laboratory space for start-up companies with the opening of the CoLaborator, a 550-m2 (5920.150 ft2) shared laboratory for start-up life-sciences companies whose technology platforms, drug targets, or drug candidates align with Bayer's portfolio. The CoLaborator is expected to house three or four small companies. Bayer plans to launch the facility by late summer 2012 at its Mission Bay, California, location. Read More
Advertisement:
Learn how you can use analytical tools to make scientific discoveries not possible by other means. SYNAPT G2-S from Waters gives you access to the highest levels of information content from your most analytically challenging samples. The combination of StepWave ion optics, QuanTof analyzer, and High Definition MS technologies maximize your chance of success to deliver all-inclusive qualitative and quantitative performance.
 Find out more
|
ShangPharma, a CRO, has opened a new facility for Eli Lilly. The newly opened facility adds 110,000 ft2 of laboratory and office space to the company's overall capacity and will support Lilly's ongoing and future projects. The opening of the facility coincides with the multiyear extension of ShangPharma's contract with Lilly. Read More
Advertisement:
Today’s product lifecycle is moving at a speed like never before. With more and more businesses rushing their products to market in order to keep up with this pace, bringing visibility to quality becomes a challenge. Learn how Risk Management provides the framework for handling adverse events in a systematic way—from design, to post-market events, to tracking and trending risk across the enterprise.  http://www.etq.com/internet/pharmtech/risk-lifecycle/?utm_campaign=pharmtech-email-risktoolswp |
Sigma-Aldrich has agreed to acquire BioReliance Holdings, a provider of biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash. The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012. Read More
Xoma, a biotechnology company, has announced organizational and structural changes that are designed to reduce manufacturing costs as part of an overall cost-cutting effort. The company plans to reduce personnel by 84 positions, including 50 positions to be eliminated immediately and the remainder by the end of the first quarter of this year. The staff reductions result primarily from the company's decisions to outsource its Phase III and commercial production operations to contract service providers. This reduction in fixed costs allows investment of a similar amount into gevokizumab's clinical development during 2012. Read More
In other news:
AAIPharma Services has acquired Celsis Analytical Services, a division of Celsis International.
Albany Molecular Research (AMRI) has entered into a preferred provider agreement with BioPontis Alliance.
AMRI will review its Hungary operations as part of a possible restructuring of its European operations.
Astellas and Theravance have terminated their license, development, and commercialization agreement for Vibativ (telavancin) for injection, a once-daily lipoglycopeptide antibiotic.
Biogen Idec and Isis Pharmaceuticals have formed a collaboration for an antisense drug.
Endo Pharmaceuticals and BioDelivery Sciences International have signed a licensing agreement for buprenorphine, a partial mu-opiate receptor agonist using bioerodible mucoadhesive technology.
Forma has formed a drug-development deal with Janssen Biotech focused on tumor metabolism.
Forma has also formed a drug-development pact with Boehringer Ingelheim focused on novel oncology drugs.
Gilead Sciences provides update on its acquisition of Pharmasset.
GlaxoSmithKline has exercised the option to license ChemoCentryx's CCR1 inhibitor, CCX354, for the treatment of rheumatoid arthritis.
Goodwin Biotechnology has signed an antibody manufacturing pact with OncoMax.
ICON has signed a partnership with Shire Specialty Pharmaceuticals to serve as its sole global provider of central laboratory services.
MonoSol Rx and Midatech have launched MidaSol Therapeutics, a joint venture focused on the commercialization of diabetes therapies.
Pfenex and ProZyme have entered into a joint collaboration and protein-supply agreement.
Recipharm will supply mangafodipir, a drug in clinical development by PledPharma.
Sanofi is coinvesting in Warp Drive Bio, a start-up biotechnology company focused on proprietary genomic technology to discover drugs of natural origin, along with two venture capital firms, Third Rock Ventures and Greylock Partners.
Sanofi also formed a $3.1-million alliance with the University of California at San Francisco for diabetes research.
Sanofi also formed a partnership with Foundation Medicine for potential diagnostics for select Sanofi oncology drugs.
Thermo Fisher Scientific introduces Unity Lab Services, product and laboratory services.
Do you have news to report on facility expansions, contracts, service agreements, mergers, acquisitions, or personnel appointments? Send press releases to ptpress@advanstar.com |
|
|
|
|
|
|
|
|
Lyophilization advances
Is lyophilization technology advancing fast enough to meet demands from manufacturers of increasingly sensitive biopharmaceutical products?
|
View the poll archive. |
|
|
|
